Blueprint Medicines (NASDAQ: BPMC) is one of 185 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare Blueprint Medicines to similar companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.
Earnings and Valuation
This table compares Blueprint Medicines and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Blueprint Medicines||$27.77 million||-$72.49 million||-19.75|
|Blueprint Medicines Competitors||$217.29 million||-$39.39 million||-71.18|
Insider and Institutional Ownership
91.4% of Blueprint Medicines shares are held by institutional investors. Comparatively, 49.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 3.4% of Blueprint Medicines shares are held by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of recent recommendations for Blueprint Medicines and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Blueprint Medicines Competitors||530||2393||6571||123||2.65|
Blueprint Medicines presently has a consensus target price of $75.13, indicating a potential upside of 11.54%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.39%. Given Blueprint Medicines’ competitors higher possible upside, analysts clearly believe Blueprint Medicines has less favorable growth aspects than its competitors.
This table compares Blueprint Medicines and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Blueprint Medicines Competitors||-3,356.81%||-100.36%||-39.83%|
Volatility and Risk
Blueprint Medicines has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Blueprint Medicines’ competitors have a beta of 1.58, meaning that their average share price is 58% more volatile than the S&P 500.
About Blueprint Medicines
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.